

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

February 14, 2024

Chordia CEO to Speak at the Japan Healthcare Venture Summit 2023 Symposium

Kanagawa, Japan,

February 14, 2024 – Chordia Therapeutics K.K. (Head Office: Fujisawa City, Kanagawa Prefecture; President: Hiroshi Miyake) is pleased to announce that our President and CEO, Mr. Miyake, spoke at the Japan Healthcare Venture Summit 2023 Symposium on February 10, 2024. This symposium aims to accelerate the practical application of the excellent seeds and ideas possessed by medical ventures in Japan and to support them. The event will provide an opportunity to expand the startup ecosystem through the introduction of various policies and industry trends surrounding medical ventures, as well as panel discussions by various industry players. This event will serve as an opportunity to publicize the efforts being made to revitalize the medical venture industry and to further promote the development and commercialization of innovative pharmaceuticals, medical devices, and regenerative medicines by utilizing these efforts.

*This event is part of the "Japan Healthcare Venture Summit 2023" which was originally held in October 2023 under the auspices of the Ministry of Health, Labor and Welfare.

About the Japan Healthcare Venture Summit 2023 symposium

This event is organized by the Ministry of Health, Labor and Welfare (MHLW) to provide a venue for medical ventures to have exhibit booths and to make presentations to promote networking and matching with key persons from major companies, financial institutions, research organizations, etc., and to create an environment to deepen understanding of the current status of regulations and related systems and venture support efforts among related persons.

About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers. Chordia's lead asset CLK inhibitor CTX-712 is under Phase 1 clinical study in Japan. CTX-712 potentially targets the vulnerability of cancer and is expected to deliver benefit to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

info@chorditherapeutics.com



Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact IR Mizobe: ir@chorditherapeutics.com